Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

BioRestorative Therapies (BRTX) Debt to Equity (2016 - 2025)

BioRestorative Therapies (BRTX) has disclosed Debt to Equity for 15 consecutive years, with $0.89 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Debt to Equity rose 157.89% year-over-year to $0.89, compared with a TTM value of $0.89 through Sep 2025, up 157.89%, and an annual FY2024 reading of $0.3, up 12.91% over the prior year.
  • Debt to Equity was $0.89 for Q3 2025 at BioRestorative Therapies, up from $0.53 in the prior quarter.
  • Across five years, Debt to Equity topped out at $3.69 in Q2 2023 and bottomed at -$1.21 in Q3 2021.
  • Average Debt to Equity over 5 years is $0.59, with a median of $0.42 recorded in 2024.
  • The sharpest move saw Debt to Equity skyrocketed 2672.54% in 2022, then tumbled 88.73% in 2024.
  • Year by year, Debt to Equity stood at $0.03 in 2021, then surged by 1779.44% to $0.54 in 2022, then plummeted by 51.41% to $0.26 in 2023, then grew by 12.91% to $0.3 in 2024, then soared by 201.83% to $0.89 in 2025.
  • Business Quant data shows Debt to Equity for BRTX at $0.89 in Q3 2025, $0.53 in Q2 2025, and $0.51 in Q1 2025.